There are many well-accepted indications for cytogenetic testing indicated by the detection of a fetal abnormality on prenatal ultrasound. Over the last decade, the molecular bases for thousands of single gene disorders have been elucidated, molecular cytogenetic tests have been created, and molecular assays for most infectious agents have been developed-potentially improving our ability to make accurate prenatal diagnoses. This review describes the role of molecular diagnostics in detecting chromosomal microdeletions and microduplications, single gene disorders, and infectious diseases. We show that molecular genetic testing is now frequently indicated in the evaluation of abnormal ultrasound findings. A significant educational effort will be necessary to incorporate new molecular knowledge into obstetric ultrasound practice.
INTRODUCTION
Cytogenetic testing is routinely offered whenever certain fetal anomalies are seen on a prenatal ultrasound examination. "Molecular cytogenetic" tests have expanded our capacity to make a definitive prenatal diagnosis (i.e. fluorescence in situ hybridization (FISH) for 22q11 deletion when conotruncal or aortic arch abnormalities are seen). Over the past decade, the molecular bases for thousands of single gene disorders have been elucidated, potentially improving our ability to make accurate prenatal diagnoses of hundreds of single gene disorders as well. Now, polymerase chain reaction (PCR)-based tests are improving our capability to screen for in utero infections suggested by ultrasound findings.
Both as a clinician and a director of a diagnostic laboratory, I have observed that an increasing number of DNA based tests are being ordered solely because of a prenatal ultrasound finding ( Table 1) . The literature provides relatively little guidance on accepted indications for molecular genetic testing in contrast to the widely-used standard indications for prenatal cytogenetic testing. This review is intended to serve as a preliminary map for this rapidly-emerging but largely-uncharted complement to modern prenatal diagnosis by sonography. 
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of Fallot and possibly a cleft palate. Amniocentesis was performed for karyotype analysis and for fluorescence in situ hybridization (FISH) using a chromosome 22 probe. The FISH results confirmed that the fetus had a submicroscopic deletion of chromosome 22(del 22q11.2). Individuals with this deletion syndrome have congenital heart disease (74%), particularly conotruncal malformations (tetralogy of Fallot, interrupted aortic arch, ventricular septal defect, and truncus arteriosus) and palatal abnormalities (69%). 1 The syndrome can also include characteristic facial features, learning difficulties, an immune deficiency, hypocalcemia (50%), significant feeding problems (30%), renal anomalies (37%), hearing loss, laryngotracheoesophageal anomalies, autoimmune disorders, seizures, and skeletal abnormalities. In this instance, the parents were appreciative of the specific information we were able to provide as a result of the microdeletion diagnosis. They elected to carry the pregnancy to term. Knowledge of the deletion allowed anticipatory care during the pregnancy and proper neonatal testing and care after birth.
Microdeletions, Microduplications, and Microarrays
In Case Example A, a fluorescence in situ hybridization (FISH ) probe was used to detect a specific suspected microdeletion syndrome because of the prenatal ultrasound findings. Many prenatal observable defects have been associated with microdeletions or microduplications ( Table 2) . A new technology now allows easy and conclusive screening for these previously under-appreciated genetic underpinnings for human malformation.
Chromosomal microarray (CMA) chips have hundreds to millions of molecules (oligonucleotides, cloned DNA, etc.) arrayed on a surface. 2 The attached molecules are used to probe a variety of chromosomal regions simultaneously. Manufacturers can place picogram amounts of a probe at defined locations, and each probe can be just a few micrometers apart. The molecular probes may be attached to plastic, glass, nylon, or even silicon wafers. Each individual probe is placed at a precisely defined location on the array support, which is usually a flat, two-dimensional surface. The identity of the molecule fixed to each spot for any particular array design never changes. The microscopic scale of the array keeps assay costs lower and allows high-throughput "parallel" testing of clinical samples.
Regardless of the array design, hybridization (the ability of two complementary nucleic acid molecules to lock together based upon Watson-Crick base-pairing) is the critical feature. Single-stranded DNA probes will hybridize or "stick" to the strands of DNA sample to be tested following the usual rules of base pairing (A to T, C to G). Complementary DNA sequences have incredibly high affinity for each other and thus the target DNA in a solution literally "find" and attach itself to the immobilized probe DNA. Probes as short as 20 nucleotides in length can be highly specific; while even a single mismatched base will greatly reduce the strength and likelihood of hybridization. Thus, highly specific DNA capture molecules can be designed and prepared either by chemical synthesis or by using PCR.
The probes which are fixed onto the array surface capture the nucleic acid to be tested which is in a solution applied to the array. Most microarrays use fluorescent tags as the means of identifying whether hybridization has occurred (whether the target molecule is stuck to the probe molecule on the array). Array scanners can rapidly detect very low levels of fluorescence and map the signal to its source on the array with great certainty. Usually the fluorescent tags are excited by a laser and the signal captured by a high-resolution 'digital' camera. Most protocols improve sensitivity of detection by chemically attaching more than one copy of fluorescent tag per target molecule detected.
With chromosomal microarrays, it is possible to perform a "molecular karyotype". 3 The resolution of a CMA is better than the resolution of conventional cytogenetics and no culture time is required. Furthermore, probes can be included for all of the microdeletion regions commonly tested by ancillary fluorescent in situ hybridization (FISH) tests (i.e. Di George syndrome caused by a chromosome 22 microdeletion). Moreover, all of these common microdeletion regions can be tested in parallel, rather than one at a time. The patterns obtained on arrays are easier to read by computer compared to G-banded metaphase spreads. Although CMAs cannot detect low-level mosaicism or balanced rearrangements, it can detect many important abnormalities missed by conventional cytogenetics. A CMA is such a sensitive test for small duplications and microdeletions, genetic variants of unknown clinical significance will be detected. Blood from both parents will usually be requested to help determine the significance of these findings. Prenatal CMA can detect the disorders that are usually identified by karyotypic analysis, including Down syndrome, trisomy 13, trisomy 18, sex chromosomal abnormalities.
A CMA testing can be performed on CVS, amniocentesis, or fetal blood. It is likely that CMA will become the preferred method for the prenatal diagnosis of chromosomal abnormalities.
CASE EXAMPLE B
An ultrasound performed because the patient was measuring "large-for-dates" at 20 weeks' gestation showed isolated idiopathic polyhydramnios. A karyotype was performed and it was normal. Subsequently, positional deformities of the fetal hands and feet were observed. The fetus had congenital myotonic dystrophy by DNA triplet repeat mutation analysis. 
Single Gene Disorders
The Online Mendelian Inheritance in Man database now lists over 10,000 human diseases which are caused by defects in single genes. 4 Most of these monogenic disorders are individually very rare but they affect about 1 percent of the population as a whole. The DNA testing is clinically available for several hundred of these disorders (see www,genetests.org for current information about available tests). 1 Many of these monogenic conditions can cause significant anatomic findings on prenatal ultrasound. The DNA testing in response to some ultrasound findings has become routine. For instance, testing for thalassemia has been part of the evaluation of the fetus with non-immune hydrops for decades now. Similarly, since the discovery of the cystic fibrosis gene in 1988, an ultrasound suggesting meconium peritonitis usually prompts cystic fibrosis mutation testing.
Unfortunately, most monogenic conditions need to be screened for one at a time depending upon the anatomic findings. Our knowledge of human single gene disorders is still developing. As a result, for some disorders, the available DNA test cannot give a conclusive answer (i.e. when the disease is caused by more than one gene and only one of the causative genes has been discovered) or it cannot suggest severity or extent of the disease. This list of potential ultrasound findings caused by single gene disorders and the list of associated genes is very long. Table 3 lists several common neonatal or prenatal ultrasound findings, and suggests a differential diagnosis of syndromes and single gene disorders in which that particular finding as a common feature of the genetic disorder.
5 Table 3 also indicates whether clinical DNA testing is available for the disorder in the United States as of October 2006. 1 In the near future, panels will be developed to test for all of the conditions associated with a particular ultrasound finding. This should increase utilization of DNA testing to diagnose important but uncommon conditions associated with isolated ultrasound findings.
CASE EXAMPLE C
A TORCH infection was suspected when a fetus was found to have ascites and hepatic calcifications. In addition to sending maternal serologies, amniotic fluid cultures, and amniotic fluid for various PCR-based assays for individual pathogens, amniotic fluid was also tested using a prototype microarray designed to screen for all common infectious agents capable of impacting a fetus. The microarray showed the offending organism to be cytomegalovirus (CMV) in just a few hours, long before the other test results were available. The patient received extensive counseling about CMV infections late in gestation. 
Infectious Pathogens
Diagnostic assays for acute infections are rapidly changing from antibody detection to pathogen detection, from slower culture based methods to rapid molecular methods, from clinical laboratory based to point-of-care (POC)-based tests, and from detection of only a few types of organisms at a time to simultaneous detection of multiple pathogens. 6 Microarrays have the ability to detect viruses, bacteria, and other microorganisms all on the same chip. They can detect the organisms even when they are no longer alive. Very rapid testing is possible and sample handling is very simple. Microarrays are also being used to monitor both innate and adaptive immunity; others are studying global gene expression of both the pathogen and the patient during the progression of an infection. In the near future, virulence factors, resistance factors, and host response to the pathogen will all be monitored in parallel. Rapid POC devices will allow rapid screens on amniotic fluid in the setting of a suspected TORCH infection or chorioamnionitis.
CONCLUSIONS
Molecular genetic testing frequently aids in the evaluation of abnormal ultrasound findings. Hundreds of new assays are being developed every year. A significant educational effort will be necessary to incorporate new molecular knowledge into obstetric ultrasound practice. It is hoped that these tables and their primary sources will be helpful references for all those involved in state-of-the-art prenatal diagnosis.
